Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.

Intimal thickening, the accumulation of cells and extracellular matrix within the inner vessel wall, is a physiological response to mechanical injury, increased wall stress, or chemical insult (e.g., atherosclerosis). If excessive, it can lead to the obstruction of blood flow and tissue ischemia. Together with expansive or constrictive remodeling, the extent of intimal expansion determines final lumen size and vessel wall thickness. Plaque rupture represents a failure of intimal remodeling, where the fibrous cap overlying an atheromatous core of lipid undergoes catastrophic mechanical breakdown. Plaque rupture promotes coronary thrombosis and myocardial infarction, the most prevalent cause of premature death in advanced societies. The matrix metalloproteinases (MMPs) can act together to degrade the major components of the vascular extracellular matrix. All cells present in the normal and diseased blood vessel wall upregulate and activate MMPs in a multistep fashion driven in part by soluble cytokines and cell-cell interactions. Activation of MMP proforms requires other MMPs or other classes of protease. MMP activation contributes to intimal growth and vessel wall remodeling in response to injury, most notably by promoting migration of vascular smooth muscle cells. A broader spectrum and/or higher level of MMP activation, especially associated with inflammation, could contribute to pathological matrix destruction and plaque rupture. Inhibiting the activity of specific MMPs or preventing their upregulation could ameliorate intimal thickening and prevent myocardial infarction.

[1]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Sasaguri,et al.  Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. , 1991, Atherosclerosis.

[3]  J. McEwan,et al.  Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. , 1999, Circulation.

[4]  S. Kaul,et al.  Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. , 1999, Circulation.

[5]  M. Davies The pathophysiology of acute coronary syndromes , 2000, Indian heart journal.

[6]  S. Weiss,et al.  Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. , 2001, Journal of vascular surgery.

[7]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[8]  A. Clowes,et al.  Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. , 1997, Circulation research.

[9]  A. Newby,et al.  Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[10]  B. Strauss,et al.  In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. , 1996, Circulation research.

[11]  F. Soubrier,et al.  Clinical implications of the molecular biology of the renin-angiotensin system. , 1990, European heart journal.

[12]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[13]  WolfgangKoenig,et al.  Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[14]  P. Libby,et al.  Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.

[15]  É. Allaire,et al.  Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.

[16]  S E Nissen,et al.  Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study. , 2000, Circulation.

[17]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[18]  Jason L Johnson,et al.  Characteristics of Intact and Ruptured Atherosclerotic Plaques in Brachiocephalic Arteries of Apolipoprotein E Knockout Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[19]  K. Siddle,et al.  Defect in Insulin-Like Growth Factor-1 Survival Mechanism in Atherosclerotic Plaque-Derived Vascular Smooth Muscle Cells Is Mediated by Reduced Surface Binding and Signaling , 2001, Circulation research.

[20]  M. Davies,et al.  Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. , 1996, Circulation research.

[21]  M. Ferguson,et al.  Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. , 1996, The American journal of pathology.

[22]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[23]  M. Aoyagi,et al.  Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation , 1998, Histochemistry and Cell Biology.

[24]  M. Ferguson,et al.  Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. , 1993, Circulation research.

[25]  V. Fuster,et al.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. , 1995, Circulation.

[26]  J. K. Lee,et al.  Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. , 1999, Biochemical and biophysical research communications.

[27]  A. Baker,et al.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. , 1998, The Journal of clinical investigation.

[28]  A. Newby Vitronectin is implicated as the matrix takes control of neointima formation. , 2002, Cardiovascular research.

[29]  D. Reed,et al.  Are Aortic Aneurysms Caused by Atherosclerosis? , 1992, Circulation.

[30]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[32]  P. Wolters,et al.  Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. , 1999, Journal of immunology.

[33]  P. Libby,et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.

[34]  M. Jeune,et al.  Enhanced Expression of Matrix Metalloproteinase‐3, ‐12, and ‐13 mRNAs in the Aortas of Apolipoprotein E‐deficient Mice with Advanced Atherosclerosis , 1999, Annals of the New York Academy of Sciences.

[35]  A. Newby,et al.  Gene Therapy for All Aspects of Vein‐Graft Disease , 2002, Journal of cardiac surgery.

[36]  D. Woolley,et al.  Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries , 1999, The Journal of pathology.

[37]  C. Napoli,et al.  Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E‐deficient and LDL receptor‐deficient mice , 2001, The Journal of pathology.

[38]  A. Baker,et al.  Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins , 1998, Gene Therapy.

[39]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[40]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[41]  T. Ley,et al.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Jackson,et al.  Mechanisms underlying maintenance of smooth muscle cell quiescence in rat aorta: role of the cyclin dependent kinases and their inhibitors. , 2002, Cardiovascular research.

[43]  A. Cho,et al.  Matrix Metalloproteinase-9 Is Necessary for the Regulation of Smooth Muscle Cell Replication and Migration After Arterial Injury , 2002, Circulation research.

[44]  W. Parks,et al.  Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. , 2000, Gene.

[45]  C. López-Otín,et al.  Differential Effects of Transforming Growth Factor-β on the Expression of Collagenase-1 and Collagenase-3 in Human Fibroblasts* , 1998, The Journal of Biological Chemistry.

[46]  E. Nabel,et al.  Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.

[47]  Z. Galis,et al.  Expansive Arterial Remodeling Is Associated With Increased Neointimal Macrophage Foam Cell Content: The Murine Model of Macrophage-Rich Carotid Artery Lesions , 2002, Circulation.

[48]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[49]  G. Amorino,et al.  Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. , 1998, The American journal of pathology.

[50]  P. Thorén,et al.  Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  W. Pearce,et al.  In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[52]  P. Slocombe,et al.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. , 1998, FEBS letters.

[53]  E. Nabel,et al.  Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. , 2000, Circulation.

[54]  W. Koenig,et al.  Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[55]  H. Lijnen,et al.  Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. , 1999, Circulation research.

[56]  Julie H. Campbell,et al.  Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with phenotype. , 1990, The Biochemical journal.

[57]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[58]  M. Crow,et al.  Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. , 1998, Circulation.

[59]  S. Schwartz,et al.  Monoclonality of smooth muscle cells in human atherosclerosis. , 1997, The American journal of pathology.

[60]  T. Ugarova,et al.  Differential Induction of Gelatinase B (MMP-9) and Gelatinase A (MMP-2) in T Lymphocytes upon α4β1-Mediated Adhesion to VCAM-1 and the CS-1 Peptide of Fibronectin☆ , 2000 .

[61]  T. Haas,et al.  Three-dimensional Type I Collagen Lattices Induce Coordinate Expression of Matrix Metalloproteinases MT1-MMP and MMP-2 in Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[62]  A. Zalewski,et al.  Role of matrix metalloproteinases and their tissue inhibitors in the regulation of coronary cell migration. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[63]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[64]  S. Schwartz,et al.  Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery , 1985, Circulation research.

[65]  WulfPalinski,et al.  Unraveling Pleiotropic Effects of Statins on Plaque Rupture , 2002 .

[66]  Y. Okada,et al.  Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules* , 1997, The Journal of Biological Chemistry.

[67]  J. Chamley-Campbell,et al.  What controls smooth muscle phenotype? , 1981, Atherosclerosis.

[68]  X. Han,et al.  Transcriptional Up-regulation of Endothelial Cell Matrix Metalloproteinase-2 in Response to Extracellular Cues Involves GATA-2* , 2003, Journal of Biological Chemistry.

[69]  R. Timpl Macromolecular organization of basement membranes. , 1996, Current opinion in cell biology.

[70]  B. Paigen,et al.  Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. , 1990, Arteriosclerosis.

[71]  Peter Tontonoz,et al.  Liver X Receptor-dependent Repression of Matrix Metalloproteinase-9 Expression in Macrophages* , 2003, The Journal of Biological Chemistry.

[72]  R. Virmani,et al.  Histopathologic analysis of in‐stent neointimal regression in a porcine coronary model , 2000, Coronary artery disease.

[73]  S. George,et al.  Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[74]  Steven M. Holland,et al.  Mechanical Stretch Enhances mRNA Expression and Proenzyme Release of Matrix Metalloproteinase‐2 (MMP‐2) via NAD(P)H Oxidase‐Derived Reactive Oxygen Species , 2003, Circulation research.

[75]  M. Hollenberg,et al.  Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. , 2001, The Biochemical journal.

[76]  D. Bowyer,et al.  A standardised method of culturing aortic explants, suitable for the study of factors affecting the phenotypic modulation, migration and proliferation of aortic smooth muscle cells. , 1991, Atherosclerosis.

[77]  J. McEwan,et al.  Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[78]  E. Lakatta,et al.  Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. , 1996, The American journal of pathology.

[79]  B. Sumpio,et al.  Transcription Factor Sp1 Phosphorylation Induced by Shear Stress Inhibits Membrane Type 1-Matrix Metalloproteinase Expression in Endothelium* , 2002, The Journal of Biological Chemistry.

[80]  F. Lupu,et al.  Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[81]  E. Fleck,et al.  Endoproteolytic Activation of &agr;v Integrin by Proprotein Convertase PC5 Is Required for Vascular Smooth Muscle Cell Adhesion to Vitronectin and Integrin-Dependent Signaling , 2004, Circulation.

[82]  P. Libby,et al.  Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.

[83]  C. Brinckerhoff,et al.  The AP-1 site and MMP gene regulation: what is all the fuss about? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[84]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein , 1998 .

[85]  M. Pepper Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[86]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[87]  F J Schoen,et al.  Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[88]  P. Slocombe,et al.  TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 , 1998 .

[89]  U. Ikeda,et al.  Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. , 2000, Journal of cardiovascular pharmacology.

[90]  U. Ikeda,et al.  Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. , 2000, Journal of molecular and cellular cardiology.

[91]  M. Bennett,et al.  IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS , 2003, Heart.

[92]  Y. Okada,et al.  Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. , 1999, European journal of biochemistry.

[93]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[94]  J. Berger,et al.  Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 Cells , 2000 .

[95]  M. Reidy,et al.  The Role of Plasminogen Activation in Smooth Muscle Cell Migration after Arterial Injury , 1992, Annals of the New York Academy of Sciences.

[96]  E. Lakatta,et al.  Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. , 1994, Circulation research.

[97]  M. Makuuchi,et al.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis , 2002, Nature Medicine.

[98]  A. Borczuk,et al.  ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. , 2001, The Journal of clinical investigation.

[99]  A. Newby,et al.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.

[100]  H. Klocker,et al.  Androgen Receptor-Ets Protein Interaction Is a Novel Mechanism for Steroid Hormone-mediated Down-modulation of Matrix Metalloproteinase Expression* , 1996, The Journal of Biological Chemistry.

[101]  V. V. van Hinsbergh,et al.  Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.

[102]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[103]  A. Zalewski,et al.  Diverse Origin of Intimal Cells: Smooth Muscle Cells, Myofibroblasts, Fibroblasts, and Beyond? , 2002, Circulation research.

[104]  C. Soria,et al.  Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.

[105]  A. Newby,et al.  Monocyte adhesion to human saphenous vein in vitro. , 1991, Atherosclerosis.

[106]  H. Mühl,et al.  IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNFα blockage and modulation by IL-10 , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[107]  Stephen M. Schwartz,et al.  Advanced Atherosclerotic Lesions in the Innominate Artery of the ApoE Knockout Mouse , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[108]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[109]  D. Collen,et al.  Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene , 2002, Circulation research.

[110]  James P. Quigley,et al.  Matrix Metalloproteinase-2 Is an Interstitial Collagenase , 1995, The Journal of Biological Chemistry.

[111]  A. Morgan,et al.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease , 2003, Journal of Molecular Medicine.

[112]  E. P. Moiseeva Adhesion receptors of vascular smooth muscle cells and their functions. , 2001, Cardiovascular research.

[113]  Giulio Gabbiani,et al.  Arterial Smooth Muscle Cell Heterogeneity: Implications for Atherosclerosis and Restenosis Development , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[114]  M. Shibata,et al.  Apoptotic detection methods--from morphology to gene. , 2003, Progress in histochemistry and cytochemistry.

[115]  A. Clowes,et al.  Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[116]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[117]  D. Woolley,et al.  Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. , 1994, European journal of biochemistry.

[118]  T. Shofuda,et al.  Cleavage of Focal Adhesion Kinase in Vascular Smooth Muscle Cells Overexpressing Membrane-Type Matrix Metalloproteinases , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[119]  J. Campbell,et al.  Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. , 1985, Experimental and molecular pathology.

[120]  J. Campbell,et al.  Culture techniques and their applications to studies of vascular smooth muscle. , 1993, Clinical science.

[121]  J. McEwan,et al.  TIMP‐4 Is Regulated by Vascular Injury in Rats , 1999, Circulation research.

[122]  A M Zeiher,et al.  Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.

[123]  R. Dilley,et al.  A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia. , 1988, Archives of surgery.

[124]  D. Harrison,et al.  Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. , 1996, The Journal of clinical investigation.

[125]  M. Jeune,et al.  Effect of Matrix Metalloproteinase Inhibition on Progression of Atherosclerosis and Aneurysm in LDL Receptor‐Deficient Mice Overexpressing MMP‐3, MMP‐12, and MMP‐13 and on Restenosis in Rats after Balloon Injury , 1999, Annals of the New York Academy of Sciences.

[126]  Z. Galis,et al.  Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[127]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.

[128]  B Hillen,et al.  Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. , 1998, Journal of the American College of Cardiology.

[129]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[130]  M. Weiser-Evans,et al.  Changes in Perlecan Expression During Vascular Injury: Role in the Inhibition of Smooth Muscle Cell Proliferation in the Late Lesion , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[131]  P. Carmeliet,et al.  Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. , 1997, Circulation research.

[132]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[133]  R. Stoney,et al.  Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[134]  A. Zalewski,et al.  Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. , 1996, Circulation.

[135]  S. Itohara,et al.  Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia , 2003, Circulation.

[136]  Z. Galis,et al.  Expression of Matrix Metalloproteinase-9 in Endothelial Cells Is Differentially Regulated by Shear Stress , 2003, Journal of Biological Chemistry.

[137]  G. Cherr,et al.  Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[138]  Julie H. Campbell,et al.  Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. , 1998, Journal of vascular surgery.

[139]  A. Clowes,et al.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.

[140]  Carol Cass,et al.  Nitric Oxide and Cyclic GMP Increase the Expression of Matrix Metalloproteinase-9 in Vascular Smooth Muscle , 2003, Journal of Pharmacology and Experimental Therapeutics.

[141]  M. Reidy,et al.  Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. , 1996, Circulation research.

[142]  G. Zhou,et al.  Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. , 2000, Biochemical and biophysical research communications.

[143]  Y. Nagashima,et al.  Elevated expression of membrane-type 1 and 3 matrix metalloproteinases in rat vascular smooth muscle cells activated by arterial injury. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[144]  A. Henney,et al.  Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. , 1994, British heart journal.

[145]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[146]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[147]  S. George,et al.  Formation in Organ Cultures of Human Saphenous Vein Expression of Tissue Inhibitor of Metalloproteinase-1 ,2 , and-3 During Neointima , 1999 .

[148]  J. Blankensteijn,et al.  Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. , 2004, Journal of vascular surgery.

[149]  D. Nance,et al.  Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. , 1995, The Journal of clinical investigation.

[150]  R. Ross,et al.  Atherosclerosis and the Arterial Smooth Muscle Cell , 1973 .

[151]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[152]  M. Reidy,et al.  Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. , 1994, Circulation research.

[153]  G. Angelini,et al.  The future of saphenous vein as a coronary artery bypass conduit. , 1989, European heart journal.

[154]  P. Libby,et al.  Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.

[155]  E. Stringa,et al.  Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells. , 2000, Journal of cell science.

[156]  Z. Galis,et al.  N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? , 1998, Circulation.

[157]  A. Gotlieb,et al.  Endothelial stimulation of intimal cell proliferation in a porcine aortic organ culture. , 1989, The American journal of pathology.

[158]  A. Woods,et al.  Syndecan proteoglycans and cell adhesion. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[159]  Jason L. Johnson,et al.  Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. , 2001, Atherosclerosis.

[160]  C. Brinckerhoff,et al.  Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle‐derived cell line , 1993, Journal of cellular physiology.

[161]  L. Petit,et al.  Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. , 1999, Circulation.

[162]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. , 1998, Human gene therapy.

[163]  K. Schrör,et al.  Factor Xa Releases Matrix Metalloproteinase-2 (MMP-2) From Human Vascular Smooth Muscle Cells and Stimulates the Conversion of Pro–MMP-2 to MMP-2: Role of MMP-2 in Factor Xa–Induced DNA Synthesis and Matrix Invasion , 2002, Circulation research.

[164]  A. Daugherty,et al.  Differential Effects of Doxycycline, a Broad-Spectrum Matrix Metalloproteinase Inhibitor, on Angiotensin II–Induced Atherosclerosis and Abdominal Aortic Aneurysms , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[165]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[166]  N. Nakajima,et al.  Cyclic Strain Stimulates Early Growth Response Gene Product 1–Mediated Expression of Membrane Type 1 Matrix Metalloproteinase in Endothelium , 2002, Laboratory Investigation.

[167]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[168]  M. Bennett,et al.  Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. , 2001, Pharmacology & therapeutics.

[169]  A. Clowes,et al.  Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. , 1999, Circulation research.

[170]  A. Newby,et al.  Synergistic upregulation of metalloproteinase‐9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF‐κB , 1998, FEBS letters.

[171]  C. Shanahan,et al.  Vascular Extracellular Matrix , 2002 .

[172]  E. Waubant,et al.  T cell gelatinases mediate basement membrane transmigration in vitro. , 1995, Journal of immunology.

[173]  H. Lijnen,et al.  Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[174]  P. Weissberg,et al.  Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. , 1993, Cardiovascular research.

[175]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[176]  J. Mehta,et al.  LOX-1 Mediates Oxidized Low-Density Lipoprotein-Induced Expression of Matrix Metalloproteinases in Human Coronary Artery Endothelial Cells , 2003, Circulation.

[177]  R. Ross,et al.  Expression of a disintegrin‐like protein in cultured human vascular cells and in vivo , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[178]  R. Ross,et al.  Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. , 1973, Science.

[179]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[180]  H. Birkedal‐Hansen,et al.  Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[181]  E. Benditt,et al.  Evidence for a monoclonal origin of human atherosclerotic plaques. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[182]  R. Béliveau,et al.  Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. , 2002, Journal of vascular surgery.

[183]  P. Libby,et al.  Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[184]  P. Libby,et al.  Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[185]  Jianglin Fan,et al.  Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[186]  J. Gunn,et al.  Apoptosis and cell proliferation after porcine coronary angioplasty. , 1998, Circulation.

[187]  D. Belin,et al.  Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. , 1990, Circulation research.

[188]  A. Newby,et al.  Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. , 2001, Cardiovascular research.

[189]  R. Natarajan,et al.  Diabetes-induced accelerated atherosclerosis in swine. , 2001, Diabetes.

[190]  J. Thyberg,et al.  The Synthetic Metalloproteinase Inhibitor Batimastat Suppresses Injury-Induced Phosphorylation of MAP Kinase ERK1/ERK2 and Phenotypic Modification of Arterial Smooth Muscle Cells in vitro , 2000, Journal of Vascular Research.

[191]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[192]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[193]  A. Weyrich,et al.  Differential Regulation of Matrix Metalloproteinase-9 by Monocytes Adherent to Collagen and Platelets , 2001, Circulation research.

[194]  S. George,et al.  Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. , 1993, Cardiovascular research.

[195]  J. Thyberg Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. , 1998, Histology and histopathology.

[196]  Qingbo Xu,et al.  Mouse model of venous bypass graft arteriosclerosis. , 1998, The American journal of pathology.

[197]  P. Libby,et al.  Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. , 1998, Circulation research.

[198]  J. Thyberg,et al.  Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells , 1988, The Journal of cell biology.

[199]  Jason L Johnson,et al.  3HT03-3 Matrix metalloproteinases-9 and -12 have opposite effects on atherosclerotic plaque stability , 2003 .

[200]  P R Bell,et al.  Angiogenesis and the atherosclerotic carotid plaque: association between symptomatology and plaque morphology , 1999, Journal of vascular surgery.

[201]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[202]  E. Tuzcu,et al.  Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. , 2002, The American journal of cardiology.

[203]  P. Libby,et al.  Expression of Neutrophil Collagenase (Matrix Metalloproteinase-8) in Human Atheroma: A Novel Collagenolytic Pathway Suggested by Transcriptional Profiling , 2001, Circulation.

[204]  J. Pickering,et al.  Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[205]  M. Rekhter How to evaluate plaque vulnerability in animal models of atherosclerosis? , 2002, Cardiovascular research.

[206]  G. Angelini,et al.  Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[207]  P. Libby,et al.  T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. , 1999, The American journal of pathology.

[208]  J. Thyberg,et al.  Phenotypic Modulation of Smooth Muscle Cells after Arterial Injury Is Associated with Changes in the Distribution of Laminin and Fibronectin , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[209]  J. Skepper,et al.  Acetylated Low-Density Lipoprotein Stimulates Human Vascular Smooth Muscle Cell Calcification by Promoting Osteoblastic Differentiation and Inhibiting Phagocytosis , 2002, Circulation.

[210]  W. Parks,et al.  Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. , 1995, Journal of immunology.

[211]  A. Naylor,et al.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.

[212]  P. Libby,et al.  Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[213]  D. Yue,et al.  High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. , 2003, Atherosclerosis.

[214]  D. Courtman,et al.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. , 2003, The American journal of pathology.

[215]  T. Wight,et al.  The extracellular matrix and atherosclerosis , 1995, Current opinion in lipidology.

[216]  James M. Roberts,et al.  Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors , 1996, Cell.

[217]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[218]  C. Glass,et al.  The peroxisome proliferator‐activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function , 1999 .

[219]  Alex Y Strongin,et al.  An Alternative Processing of Integrin αv Subunit in Tumor Cells by Membrane Type-1 Matrix Metalloproteinase* , 2002, The Journal of Biological Chemistry.

[220]  J. Quigley,et al.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. , 1995, The Journal of biological chemistry.

[221]  P. Libby,et al.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.

[222]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[223]  G. Angelini,et al.  Intimal proliferation in an organ culture of human saphenous vein. , 1990, The American journal of pathology.

[224]  P. Libby,et al.  Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.

[225]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[226]  Hong Wang,et al.  Transforming Growth Factor-β1 Inhibits Cytokine-mediated Induction of Human Metalloelastase in Macrophages* , 2000, The Journal of Biological Chemistry.

[227]  G. Angelini,et al.  Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. , 2000, Circulation.

[228]  Z. Galis,et al.  Remodeling of Carotid Artery Is Associated With Increased Expression of Matrix Metalloproteinases in Mouse Blood Flow Cessation Model , 2000, Circulation.

[229]  R. Khokha,et al.  Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. , 1994, The Journal of biological chemistry.

[230]  T. Watanabe,et al.  Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. , 2000, Biochemical and biophysical research communications.

[231]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[232]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[233]  J. Powell,et al.  Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[234]  R. Pruett,et al.  Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy , 1994, Nature Genetics.

[235]  B. Perler Connective tissue proteinases and inhibitors in abdominal aortic aneurysms , 1993 .

[236]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[237]  R. Black Tumor necrosis factor-alpha converting enzyme. , 2002, The international journal of biochemistry & cell biology.

[238]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[239]  S. Kawashima,et al.  Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. , 2001, Atherosclerosis.

[240]  A. von Eckardstein,et al.  Rupture of the Atherosclerotic Plaque: Does a Good Animal Model Exist? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[241]  Yan Huang,et al.  Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[242]  Jason L. Johnson,et al.  Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. , 2003, Cardiovascular research.

[243]  QingboXu,et al.  Both Donor and Recipient Origins of Smooth Muscle Cells in Vein Graft Atherosclerotic Lesions , 2002 .

[244]  A. Clowes,et al.  Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells. , 1992, Circulation research.

[245]  M. Schwartz,et al.  Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. , 2001, Journal of cell science.

[246]  M. Reidy,et al.  The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[247]  J. Thyberg Differentiated properties and proliferation of arterial smooth muscle cells in culture. , 1996, International review of cytology.

[248]  Z. Galis,et al.  Targeted Disruption of the Matrix Metalloproteinase-9 Gene Impairs Smooth Muscle Cell Migration and Geometrical Arterial Remodeling , 2002, Circulation research.

[249]  S. Kaul,et al.  Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. , 1999, Circulation.

[250]  B. Strauss,et al.  Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. , 2002, The American journal of pathology.

[251]  G. Angelini,et al.  Dismantling of Cadherin-Mediated Cell-Cell Contacts Modulates Smooth Muscle Cell Proliferation , 2003, Circulation research.

[252]  J. Thyberg,et al.  A substrate of the cell-attachment sequence of fibronectin (Arg-Gly-Asp-Ser) is sufficient to promote transition of arterial smooth muscle cells from a contractile to a synthetic phenotype. , 1989, Developmental biology.

[253]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[254]  G. Angelini,et al.  Injury Induces Dedifferentiation of Smooth Muscle Cells and Increased Matrix-Degrading Metalloproteinase Activity in Human Saphenous Vein , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[255]  W. Edwards,et al.  Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[256]  D. Edwards,et al.  Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). , 2003, The Biochemical journal.

[257]  Danny L Wang,et al.  Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. , 2004, Molecular pharmacology.

[258]  Brian J. Bennett,et al.  Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[259]  Young-Choon Lee,et al.  Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. , 2003, Biochemical and biophysical research communications.

[260]  P. Carmeliet,et al.  Temporal and Topographic Matrix Metalloproteinase Expression after Vascular Injury in Mice , 1999, Thrombosis and Haemostasis.

[261]  R. Virmani,et al.  Pathology of acute and chronic coronary stenting in humans. , 1999, Circulation.

[262]  K. Channon,et al.  Nitric Oxide Synthase (nNOS) Gene Transfer Modifies Venous Bypass Graft Remodeling: Effects on Vascular Smooth Muscle Cell Differentiation and Superoxide Production , 2001, Circulation.

[263]  François Mach,et al.  Expression of Stromelysin-3 in Atherosclerotic Lesions: Regulation via CD40–CD40 Ligand Signaling In Vitro and In Vivo , 1999, The Journal of experimental medicine.

[264]  P. Libby,et al.  Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. , 1998, Circulation research.

[265]  M. Leon,et al.  Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. , 1996, Circulation.

[266]  H. Schaff,et al.  Gene therapy for vein graft disease , 2001, Current cardiology reports.

[267]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[268]  C von Birgelen,et al.  Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. , 1995, The American journal of cardiology.

[269]  M. Davies,et al.  Atherosclerotic plaque caps are locally weakened when macrophages density is increased. , 1991, Atherosclerosis.

[270]  Z. Galis,et al.  Matrix Metalloproteinase-2 and −9 Differentially Regulate Smooth Muscle Cell Migration and Cell-Mediated Collagen Organization , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[271]  A. Newby,et al.  Regulation of Matrix Metalloproteinase (Matrixin) Genes in Blood Vessels: A Multi-Step Recruitment Model for Pathological Remodelling , 2003, Journal of Vascular Research.

[272]  B. Strauss,et al.  Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. , 2002, Journal of the American College of Cardiology.

[273]  V. Ellis Plasminogen activation at the cell surface. , 2003, Current topics in developmental biology.

[274]  R. Hershkoviz,et al.  Human Mast Cells Release Metalloproteinase-9 on Contact with Activated T Cells: Juxtacrine Regulation by TNF-α1 , 2001, The Journal of Immunology.

[275]  J. Soulillou,et al.  Antigraft Antibody-Mediated Expression of Metalloproteinases on Endothelial Cells: Differential Expression of TIMP-1 and ADAM-10 Depends on Antibody Specificity and Isotype , 2001, Circulation research.

[276]  A. Newby,et al.  Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. , 1997, Atherosclerosis.

[277]  J. D’Armiento,et al.  Increased Medial Degradation With Pseudo-Aneurysm Formation in Apolipoprotein E–Knockout Mice Deficient in Tissue Inhibitor of Metalloproteinases-1 , 2003, Circulation.

[278]  Michiko Watanabe,et al.  The Pros and Cons of Apoptosis Assays for Use in the Study of Cells, Tissues, and Organs , 2002, Microscopy and Microanalysis.

[279]  E. Topol,et al.  Strategies to achieve coronary arterial plaque stabilization. , 1999, Cardiovascular research.

[280]  H. C. Stary,et al.  The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. , 1990, European heart journal.

[281]  P. Libby,et al.  Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. , 1991, The American journal of pathology.

[282]  B. Staels,et al.  Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[283]  H. Nagase,et al.  MMPs Are IGFBP‐Degrading Proteinases: Implications for Cell Proliferation and Tissue Growth , 1999, Annals of the New York Academy of Sciences.

[284]  A. Strongin,et al.  Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrinsin breast carcinoma cells , 2003 .

[285]  A. Clowes,et al.  Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. , 1994, The Journal of clinical investigation.

[286]  J. Lettieri,et al.  LC separation and induced fluorometric detection of rivastatin in blood plasma. , 1993, Journal of pharmaceutical and biomedical analysis.

[287]  S. Kaul,et al.  Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.

[288]  J. Deux,et al.  Differential Expression of Matrix Metalloproteinases After Stent Implantation and Balloon Angioplasty in the Hypercholesterolemic Rabbit , 2001, Circulation.

[289]  L. Claesson‐Welsh,et al.  A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 , 2003, Nature Medicine.

[290]  J. Caillaud,et al.  Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. , 1999, Circulation.

[291]  Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. , 2003, Experimental cell research.

[292]  A. Baker,et al.  Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. , 1999, Biochemical and biophysical research communications.

[293]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[294]  B. Baxter,et al.  Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. , 2003, Journal of vascular surgery.

[295]  A. Newby,et al.  Role of Nuclear Factor-&kgr;B Activation in Metalloproteinase-1, -3, and -9 Secretion by Human Macrophages In Vitro and Rabbit Foam Cells Produced In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[296]  L. Lin,et al.  Basic fibroblast growth factor regulates type I collagen and collagenase gene expression in human smooth muscle cells. , 1995, The American journal of pathology.

[297]  K. Sobue,et al.  Differentiated Phenotype of Smooth Muscle Cells Depends on Signaling Pathways through Insulin-like Growth Factors and Phosphatidylinositol 3-Kinase* , 1998, The Journal of Biological Chemistry.

[298]  S. George,et al.  Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. , 1997, Cardiovascular research.

[299]  Federico Castro-Muñozledo,et al.  Commitment of 3T3-F442A cells to adipocyte differentiation takes place during the first 24-36 h after adipogenic stimulation: TNF-alpha inhibits commitment. , 2003, Experimental cell research.

[300]  Y. Sasaguri,et al.  A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. , 1998, Atherosclerosis.

[301]  P. Carmeliet Proteinases in cardiovascular aneurysms and rupture: targets for therapy? , 2000, The Journal of clinical investigation.

[302]  B. Baxter,et al.  Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. , 2002, Journal of vascular surgery.

[303]  A. Luttun,et al.  Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.

[304]  P. Shah,et al.  Increased Expression of Membrane Type 3-Matrix Metalloproteinase in Human Atherosclerotic Plaque: Role of Activated Macrophages and Inflammatory Cytokines , 2002, Circulation.

[305]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[306]  P. Libby,et al.  Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury , 1993, Circulation.

[307]  P. Libby,et al.  Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.

[308]  A. Newby,et al.  Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. , 1992, The Biochemical journal.

[309]  H. Nagase,et al.  Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[310]  H. Lijnen Plasmin and Matrix Metalloproteinases in Vascular Remodeling , 2001, Thrombosis and Haemostasis.

[311]  M. Reidy,et al.  Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.

[312]  J. Verheijen,et al.  Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon , 2000 .

[313]  P. Kovanen,et al.  TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. , 1996, Journal of immunology.

[314]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[315]  V. Kähäri,et al.  Matrix metalloproteinases in skin , 1997, Experimental dermatology.

[316]  P. Kiener,et al.  Activation of human monocytes through CD40 induces matrix metalloproteinases. , 1996, Journal of immunology.